Input to public consultation on the Swiss Ordinance on Health Insurance

5 Oct, 2016

The RDAF provided input to the public consultation launched by the Federal Office of Public Health (FOPH) on the Swiss Ordinance on Health Insurance (KVV/OAMal). The RDAF’s input included action oriented suggestions for improving patient access to treatment and focused on aspects that are most important for the area of rare diseases such as the reimbursement process applying to individual cases (the so-called article 71 KVV reimbursement process).

Joint statement on the KVV/OAMal and KLV/OPAS revision

The RDAF co-signed a joint statement with other stakeholders on the revision of the Health Insurance Ordinance (KVV/OAMal) and Health Benefits Ordinance (KLV/OPAS). The statement highlights the potential negative impacts of the revision, including the following: -...

The Rare Disease Action Forum (RDAF) advocates for a fair and rapid access to high-quality treatment for patients with rare diseases in Switzerland.

In line with this concern, the RDAF would like to draw attention to the fact that the planned revision of the Health Insurance Ordinance (KVV), contrary to its stated objective, threatens patients’ access to treatment. Read our media release here.